1 in 5 people could have obstructive sleep apnoea, and most don't know it

Publicly released:
International
Photo by Shane on Unsplash
Photo by Shane on Unsplash

One in five people may have obstructive sleep apnoea and most are unaware, according to international research. Obstructive sleep apnoea involves loud snoring and breathing that starts and stops during the night, and is associated with both tiredness and a range of health problems like high blood pressure, heart disease and diabetes. 20,151 adults in France completed a questionnaire designed to look for the signs of sleep apnoea. Among this cohort, 3.5% were being treated for the condition but 20.2% were highly likely to have it. While the researchers note this study is limited by the fact they used a questionnaire rather than sleep clinic testing, they say it shows more awareness is needed around sleep apnoea.

News release

From: European Respiratory Journal

Dangerous snoring may affect one in five people, but most sufferers do not know they have a problem

Around one in five people may be suffering with obstructive sleep apnoea (OSA), according to a study published today (Thursday) in the ERJ Open Research [1].

People with OSA often snore loudly, their breathing starts and stops during the night, and they may wake up several times. Not only does this cause tiredness, but it can also increase the risk of high blood pressure, stroke, heart disease and type 2 diabetes.

Treatments and lifestyle changes can help people with OSA. However, the new study also suggests that only a small proportion of people with symptoms of OSA have been diagnosed and are receiving help for the condition.

The study included data on 20,151 French adults. Researchers recorded how many participants had been diagnosed with OSA. They also used a questionnaire to gauge how many participants might have undiagnosed OSA. The questionnaire focuses on heavy snoring and excessive daytime sleepiness (the two most common OSA symptoms), high blood pressure and obesity.

Researchers then used this data to calculate the proportion of the French population who are likely to be affected by OSA. They found that around one in five (20.2%) were highly likely to have OSA while only 3.5% were being treated for the condition.

OSA was more common in men in people who were older, had cardiovascular disease, lower socioeconomic status or were less physically active, in smokers and in people with symptoms of depression. Women were at a higher risk of going undiagnosed with OSA.

The study was led by Dr Pauline Balagny from the Faculty of Medicine at University of Paris-Cité, France. She said: “We know that OSA is a major health hazard but if patients are diagnosed with the condition, they can be given treatments and advice to mitigate the risks. Our study suggests that OSA is common, but the majority of those affected do not know they have the condition.

“Our findings are in line with research in other countries which suggest that OSA is becoming more common."

A key strength of this research is that it is based on a large group of people who are representative of the French population. A weakness is that the study relies on a questionnaire to gauge the likelihood of OSA, rather than testing participants in a sleep clinic.

Professor Winfried Randerath, Head of the European Respiratory Society’s Assembly on sleep disordered breathing, who was not involved in the research said: “This research suggests that many people with OSA are not aware that their snoring and sleepiness are signs of a problem. We need to raise awareness of OSA because once people are diagnosed, they can be given treatment and advice to help lower their risk of other serious conditions such as stroke, heart disease and diabetes. Although OSA is more common in men, this study indicates that we also need to get better at spotting the condition in women.”

Dr Balagny and her colleagues will continue to study the links between OSA symptoms and cardiovascular diseases. They are also investigating whether screening for OSA could help heart attack patients.

(ends)

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research European Respiratory Journal, Web page The URL will go live after the embargo ends
Journal/
conference:
ERJ Open Research
Research:Paper
Organisation/s: Université Paris-Cité, France
Funder: The CONSTANCES cohort benefits from a grant from the French National Research Agency. CONSTANCES is supported by the Caisse Nationale d’Assurance Maladie, the French Ministry of Health, the Ministry of Research, and the Institut National de la Santé et de la Recherche Médicale (INSERM). CONSTANCES is also partly funded by AstraZeneca, Lundbeck, L’Oréal, and Merck Sharp & Dohme Corp. This present study was sponsored by Assistance Publique – Hôpitaux de Paris (Paris, France), supported by the Recherche Hospitalo-Universitaire (RHU) iVASC grant (www.ivasc.eu) ‘#ANR-16-RHUS-00010’ from the French National Research Agency (ANR) and funded by Plan d’Investissement d’Avenir-3 (PIA3-RHU, Ministry of Health).
Media Contact/s
Contact details are only visible to registered journalists.